+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Drugs Market Research Reports

Checkpoint Kinase 2 (Chk2) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Checkpoint Kinase 2 (Chk2) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cyclin-Dependent Kinase 1 (CDK1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cyclin-Dependent Kinase 1 (CDK1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Bcr-Abl Tyrosine Kinase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Bcr-Abl Tyrosine Kinase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
cFMS Kinase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

cFMS Kinase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Focal Adhesion Kinase (FAK) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Focal Adhesion Kinase (FAK) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
Aurora Kinase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Aurora Kinase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Non-Receptor Tyrosine Kinase Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Non-Receptor Tyrosine Kinase Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cyclin-Dependent Kinase 6/4 (CDK6/4) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Checkpoint Kinase 1 (Chk1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Checkpoint Kinase 1 (Chk1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Superoxide Dismutase (SOD) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Superoxide Dismutase (SOD) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Cathepsin K/S Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cathepsin K/S Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cathepsin K Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cathepsin K Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
IkappaB Kinase (IKK) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

IkappaB Kinase (IKK) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Loading Indicator

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more